Merck Sharp + Dohme Corp.

Other

Dizal (jiangsu) Pharmaceutical Co., Ltd.

Ares Trading S.a.

Tocopherx, Inc.

Dizal Pharmaceutical Co., Limited

Changhe Qi

Xiaolin Zhang

Zhenfan Yang

Qingbei Zeng

Honchung Tsui

Hong Shen

Richard Thomas Beresis

Anthony K Ogawa

Yuguang Wang

Ping Lan

Kun Liu

Dong-Ming Shen

Peter J Sinclair

Zhicai Wu

Henry Yu

Robert J DeVita

Paul Tempest

Alejandro Crespo

John Qiang Tan

Zhongxiang Sun

Rudrajit Mal

Min Shu

Ellen K Vande Bunte

Stephen S Palmer

Selvaraj G Nataraja

Scott D Kuduk

Casey Cameron McComas

Thomas S Reger

Christine Yang

Casey C Mccomas

Thoma S Reger

Robert J Devita

The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

Triazolo-pyrimidine compounds and uses thereof

The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

Pyrazine compounds and uses thereof

The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).

Pyrazole compounds as modulators of FSHR and uses thereof

Disclosed are pyrazole compounds, and pharmaceutically acceptable compositions thereof. The compounds and the compositions can be used for positive allosteric modulators of follicle stimulating hormone receptor (FSHR).

Compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases are disclosed. Processes for preparing compounds of the Formula (I), use of the compounds for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and pharmaceutical compositions which comprise compounds of the Formula (I) are disclosed. 

Mineralocorticoid receptor antagonists

The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.

The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Substituted pyridizinone derivatives as PDE10 inhibitors

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too. 

Growing community of inventors

Shanghai, China

Changhe Qi